These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32055804)

  • 41. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
    Scott LJ
    CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone regenerative potential of the selective sphingosine 1-phosphate receptor modulator siponimod: In vitro characterisation using osteoblast and endothelial cells.
    Sartawi Z; Ryan KB; Waeber C
    Eur J Pharmacol; 2020 Sep; 882():173262. PubMed ID: 32534075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.
    Sabsabi S; Mikhael E; Jalkh G; Macaron G; Rensel M
    Patient Prefer Adherence; 2022; 16():1307-1319. PubMed ID: 35637684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The first russian experience of use of siponimod in real clinical practice].
    Prakhova LN; Ilves AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):138-141. PubMed ID: 35904305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-inflammatory effects of siponimod on astrocytes.
    Ogasawara A; Takeuchi H; Komiya H; Ogawa Y; Nishimura K; Kubota S; Hashiguchi S; Takahashi K; Kunii M; Tanaka K; Tada M; Doi H; Tanaka F
    Neurosci Res; 2022 Nov; 184():38-46. PubMed ID: 35940437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
    Chang EH; Hardy TA
    J Neuroimmunol; 2024 Apr; 389():578330. PubMed ID: 38493554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
    Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
    Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
    Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis.
    Brand RM; Diddens J; Friedrich V; Pfaller M; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
    Chun J; Giovannoni G; Hunter SF
    Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    Spiezia AL; Scalia G; Petracca M; Caliendo D; Moccia M; Fiore A; Cerbone V; Lanzillo R; Brescia Morra V; Carotenuto A
    J Neurol; 2024 Jul; 271(7):4281-4291. PubMed ID: 38632126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.
    Wu Q; Mills EA; Wang Q; Dowling CA; Fisher C; Kirch B; Lundy SK; Fox DA; Mao-Draayer Y;
    JCI Insight; 2020 Feb; 5(3):. PubMed ID: 31935197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA.
    Ziemssen T; Hoffmann O; Klotz L; Schreiber H; Weber MS; Rauser B
    JMIR Res Protoc; 2020 Jul; 9(7):e19598. PubMed ID: 32499214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.
    Schoedel KA; Kolly C; Gardin A; Neelakantham S; Shakeri-Nejad K
    Psychopharmacology (Berl); 2022 Jan; 239(1):1-13. PubMed ID: 34773483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Sphingosine-1-Phosphate Receptor Modulator Attenuated Secondary Brain Injury and Improved Neurological Functions of Mice after ICH.
    Bobinger T; Bäuerle T; Seyler L; V Horsten S; Schwab S; Huttner HB; Manaenko A
    Oxid Med Cell Longev; 2020; 2020():3214350. PubMed ID: 32963692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage.
    Bobinger T; Manaenko A; Burkardt P; Beuscher V; Sprügel MI; Roeder SS; Bäuerle T; Seyler L; Nagel AM; Linker RA; Engelhorn T; Dörfler A; Horsten SV; Schwab S; Huttner HB
    Stroke; 2019 Nov; 50(11):3246-3254. PubMed ID: 31558140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Towards treating progressive multiple sclerosis.
    Thompson A; Ciccarelli O
    Nat Rev Neurol; 2020 Nov; 16(11):589-590. PubMed ID: 33024328
    [No Abstract]   [Full Text] [Related]  

  • 60. The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis.
    Synnott PG; Bloudek LM; Sharaf R; Carlson JJ; Pearson SD
    J Manag Care Spec Pharm; 2020 Mar; 26(3):236-239. PubMed ID: 32105176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.